Peritonitis medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | Please help WikiDoc by adding more content here. It's easy! Click [[Help:How_to_Edit_a_Page|here]] to learn about editing. | ||
{{CMG}} | {{CMG}} ;{{AE}} {{chetan}} | ||
==Medical Therapy== | ==Medical Therapy== | ||
Depending on the severity of the patient's state, the management of peritonitis may include: | Depending on the severity of the patient's state, the management of peritonitis may include: | ||
Line 22: | Line 22: | ||
<div class="mw-customtoggle-table1" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;"> | <div class="mw-customtoggle-table1" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ ''''' | ▸ '''''Primary Spontaneous Bacterial''''' | ||
</font> | </font> | ||
</div> | </div> | ||
Line 34: | Line 34: | ||
<div class="mw-customtoggle-table3" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;"> | <div class="mw-customtoggle-table3" style="cursor: pointer; border-radius: 0 0 0 0; border: solid 1px #20538D; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5); box-shadow: inset 0 1px 1px rgba(255, 255, 255, 0.5), 0 1px 1px rgba(0, 0, 0, 0.5); height: 30px; line-height: 30px; width: 250px; background: #4479BA;"> | ||
<font color="#FFF"> | <font color="#FFF"> | ||
▸ ''''' | ▸ '''''Dialysis (CAPD) Associated ''''' | ||
</font> | </font> | ||
</div> | </div> | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table1" style="background: #FFFFFF;" | |||
| valign=top | | | valign=top | | ||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible- | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center | {{fontcolor|#FFF|Primary Spontaneous Bacterial }} | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preferred Regimen''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefotaxime]] 2 gm IV q8h (q4h, if life-threatening infection) '''''<BR> OR <BR>▸'''''[[Ticaricillin Clavulanate]] 3.1 gm IV q6h '''''<BR> OR <BR>▸'''''[[Piperacillin Tazobactam]] 3.375 gm IV q6h (or 4-hour infusion of 3.375 gm q8h)'''''<BR> OR <BR>▸'''''[[Ceftriaxone]] 2 gm IV q24h'''''<BR> OR <BR>▸'''''[[Ertapenem]] 1 gm IV q24h''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''If resistant [[E. coli]] or [[Klebsiella]] species''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Imipenem]] 500 mg IV q6h '''''<BR> OR <BR>▸'''''[[Meropenem]] 1000 mg IV q8h'''''<BR> OR <BR>▸'''''[[Doripenem]] 500 mg IV q8h (1 hr infusion)''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | ''''' If checking sensitivities, then start''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 400 mg IV q12h'''''<BR> OR <BR>▸'''''[[Levofloxacin]] 750 mg IV once daily'''''<BR> OR <BR>▸'''''[[Moxifloxacin]] 400 mg IV once daily''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''In addition to antibiotic, to decrease frequency of renal impairment start''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''IV [[Albumin]] 1.5 gm/kg at diagnosis and 1 gm/kg on day 3 ''''' | |||
|- | |||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Preventive regimen for chronic ascites''''' | |||
|- | |||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸'''''[[TMP-SMX-DS]] 1 tab po 5 days/week'''''<BR> OR <BR>▸'''''[[Ciprofloxacin]] 750 mg po once/week''''' | |||
|} | |||
|} | |||
| valign=top | | |||
{| class="mw-collapsible mw-collapsed" id="mw-customcollapsible-table3" style="background: #FFFFFF;" | |||
| valign=top | | | valign=top | | ||
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | {| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;" | ||
Line 67: | Line 94: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Preferred Regimen''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Mild/Moderate Peritonitis''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' For Mild/Moderate Peritonitis''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Piperacillin Tazobactam]] 3.375 gm IV '''''<br> | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Piperacillin Tazobactam]] 3.375 gm IV '''''<br>▸'''''/ 4.5 gm IV q8h / 4-hr infusion of 3.375 gm q8h ''''' <BR> OR <BR>▸'''''[[Ticarcillin Clavulanate]] 3.1 gm IV q6h '''''<BR> OR <BR>▸'''''[[Ertapenem]] 1 gm IV q24h<BR> OR <BR>▸'''''[[Moxifloxacin]] 400 mg IV q24h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Severe Disease''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' For Severe Disease''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Imipenem]] 500 mg to 1 gm IV q6h '''''<BR> OR <BR> ▸'''''[[Meropenem]] 1 gm IV q8h'''''<BR> OR <BR>▸'''''[[Doripenem]] 500 mg IV q8h (1-hr infusion)''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Imipenem]] 500 mg to 1 gm IV q6h '''''<BR> OR <BR> ▸'''''[[Meropenem]] 1 gm IV q8h'''''<BR> OR <BR>▸'''''[[Doripenem]] 500 mg IV q8h (1-hr infusion)''''' | ||
Line 81: | Line 108: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternate Regimen''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Alternate Regimen''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Mild/Moderate Disease''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' For Mild/Moderate Disease''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[ | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] 400 mg IV q12h''''' <BR> OR <BR>'''''▸ [[Levofloxacin]] 750 mg IV q24h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | PLUS | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | PLUS | ||
Line 93: | Line 120: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metronidazole]] 1 gm IV q12h'''''<BR> OR <BR> ▸ '''''[[Tigecycline]] 100 mg IV x 1 dose, then 50 mg q12h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Metronidazole]] 1 gm IV q12h'''''<BR> OR <BR> ▸ '''''[[Tigecycline]] 100 mg IV x 1 dose, then 50 mg q12h''''' | ||
|- | |- | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | '''''Severe Disease''''' | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | ''''' For Severe Disease''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] ''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] ''''' | ||
Line 103: | Line 130: | ||
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | PLUS | | style="padding: 0 5px; font-size: 90%; background: #F5F5F5" align=center | PLUS | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] 400 mg IV q8h''''' <BR> OR <BR> ▸'''''[[Levofloxacin]] 750 mg IV q24h''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ciprofloxacin]] 400 mg IV q8h''''' <BR> OR <BR> ▸'''''[[Levofloxacin]] 750 mg IV q24h'''''<BR> OR <BR> | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 gm IV q6h ''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Ampicillin]] 2 gm IV q6h ''''' | ||
Line 115: | Line 142: | ||
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aminoglycoside]]''''' | | style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸ '''''[[Aminoglycoside]]''''' | ||
|- | |- | ||
|} | |} | ||
|} | |} |
Revision as of 19:50, 5 February 2014
Peritonitis Main Page |
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ;Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Medical Therapy
Depending on the severity of the patient's state, the management of peritonitis may include:
- General supportive measures such as vigorous intravenous rehydration and correction of electrolyte disturbances.
- Antibiotics are usually administered intravenously, but they may also be infused directly into the peritoneum. The empiric choice of broad-spectrum antibiotics often consist of multiple drugs, and should be targeted against the most likely agents, depending on the cause of peritonitis; once one or more agents are actually isolated, therapy will of course be targeted on them.
Antibiotic therapy
Peritonitis ▸ Primary Spontaneous Bacterial ▸ Secondary ▸ Dialysis (CAPD) Associated
|
|